XML 121 R122.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment and Geographic Information (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 28, 2019
[2]
Jun. 29, 2019
[3]
Mar. 30, 2019
[3]
Dec. 31, 2018
Sep. 29, 2018
[4]
Jun. 30, 2018
[5]
Mar. 31, 2018
[6]
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]                      
Net sales $ 1,322.8 [1] $ 1,191.1 $ 1,149.0 $ 1,174.5 $ 1,195.2 $ 1,133.1 $ 1,186.4 $ 1,217.0 $ 4,837.4 [7] $ 4,731.7 [7] $ 4,946.2 [7]
Operating income (loss)                 $ 204.8 $ 236.5 $ 598.2
Operating margin                 4.20% 5.00% 12.10%
Assets 11,301.4       10,983.4       $ 11,301.4 $ 10,983.4 $ 11,628.8
Capital expenditures                 137.7 102.7 88.6
Property, plant and equipment, net 902.8       829.1       902.8 829.1 833.1
Depreciation/amortization                 396.5 423.6 444.8
Change in financial assets (3.6) [1] $ (2.6) $ (5.5) $ (10.4) (122.8) $ (74.9) $ (0.6) $ 9.6 (22.1) (188.7) 24.9
CSCA                      
Segment Reporting Information [Line Items]                      
Net sales [8]                 2,487.7 2,411.6 2,429.9
Operating income (loss)                 414.0 174.4  
Assets         3,571.7         3,571.7  
CSCI                      
Segment Reporting Information [Line Items]                      
Net sales                 1,382.2 1,399.3 1,406.2
Operating income (loss)                 19.6 6.8  
Assets         4,613.0         4,613.0  
RX                      
Segment Reporting Information [Line Items]                      
Net sales                 967.5 920.8 1,054.4
Operating income (loss)                 2.6 214.6  
Assets         2,798.7         2,798.7  
Other(1)                      
Segment Reporting Information [Line Items]                      
Net sales                 0.0    
Operating income (loss)                 0.0    
Unallocated                      
Segment Reporting Information [Line Items]                      
Net sales                 0.0 0.0  
Operating income (loss)                 (231.4) (159.3)  
Ireland                      
Segment Reporting Information [Line Items]                      
Net sales                 23.4 25.7 30.4
Property, plant and equipment, net 9.3       9.8       9.3 9.8  
United States                      
Segment Reporting Information [Line Items]                      
Net sales [7]                 3,225.6 3,098.3 3,272.3
Property, plant and equipment, net 614.5       548.7       614.5 548.7  
Europe                      
Segment Reporting Information [Line Items]                      
Net sales [7],[9]                 1,335.8 1,347.6 $ 1,343.6
Property, plant and equipment, net 146.8       152.3       146.8 152.3  
Israel                      
Segment Reporting Information [Line Items]                      
Property, plant and equipment, net 86.1       77.6       86.1 77.6  
All other countries                      
Segment Reporting Information [Line Items]                      
Property, plant and equipment, net 55.4       50.5       $ 55.4 $ 50.5  
Walmart | Net sales | Customer Concentration Risk                      
Segment Reporting Information [Line Items]                      
Concentration risk percentage                 13.00% 12.80% 13.00%
Operating Segments | CSCA                      
Segment Reporting Information [Line Items]                      
Net sales                     $ 2,429.9
Operating income (loss)                     $ 470.9
Operating margin                 16.60% 7.20% 19.40%
Assets 3,990.2               $ 3,990.2   $ 3,786.8
Capital expenditures                 98.4 $ 65.0 39.5
Property, plant and equipment, net 599.8       530.3       599.8 530.3 512.8
Depreciation/amortization                 97.4 104.8 115.2
Change in financial assets                 $ 0.0 $ 0.0 0.0
Operating Segments | CSCI                      
Segment Reporting Information [Line Items]                      
Net sales                     1,406.2
Operating income (loss)                     $ (2.7)
Operating margin                 1.40% 0.50% (0.20%)
Assets 4,682.7               $ 4,682.7   $ 4,908.3
Capital expenditures                 18.8 $ 19.1 23.4
Property, plant and equipment, net 149.9       154.8       149.9 154.8 169.7
Depreciation/amortization                 194.3 219.2 219.9
Change in financial assets                 $ 0.0 $ 0.0 0.0
Operating Segments | RX                      
Segment Reporting Information [Line Items]                      
Net sales                     1,054.4
Operating income (loss)                     $ 306.1
Operating margin                 0.30% 23.30% 29.00%
Assets 2,628.5               $ 2,628.5   $ 2,933.7
Capital expenditures                 20.5 $ 18.6 25.7
Property, plant and equipment, net 153.1       144.0       153.1 144.0 150.6
Depreciation/amortization                 104.8 99.6 103.9
Change in financial assets                 $ 0.0 0.0 0.0
Operating Segments | Other(1)                      
Segment Reporting Information [Line Items]                      
Net sales                   0.0 55.7
Operating income (loss)                   $ 0.0 $ 8.7
Operating margin                 0.00% 0.00% 15.60%
Assets 0.0       0.0       $ 0.0 $ 0.0 $ 0.0
Capital expenditures                 0.0 0.0 0.0
Property, plant and equipment, net 0.0       0.0       0.0 0.0 0.0
Depreciation/amortization                 0.0 0.0 5.8
Change in financial assets                 $ 0.0 $ 0.0 0.0
Unallocated                      
Segment Reporting Information [Line Items]                      
Net sales                     0.0
Operating income (loss)                     $ (184.8)
Operating margin                 0.00% 0.00% 0.00%
Assets 0.0       0.0       $ 0.0 $ 0.0 $ 0.0
Capital expenditures                 0.0 0.0 0.0
Property, plant and equipment, net $ 0.0       $ 0.0       0.0 0.0 0.0
Depreciation/amortization                 0.0 0.0 0.0
Change in financial assets                 $ (22.1) $ (188.7) $ 24.9
[1] Includes impairment charges of $141.6 million.
 
First
Quarter
 
Second
Quarter
(2)
 
Third
Quarter
(3)
 
Fourth
Quarter
Year Ended December 31, 2018
 
 
 
 
 
 
 
Net sales
$
1,217.0

 
$
1,186.4

 
$
1,133.1

 
$
1,195.2

Gross profit
$
492.7

 
$
471.0

 
$
424.8

 
$
443.0

Change in financial assets
$
9.6

 
$
(0.6
)
 
$
(74.9
)
 
$
(122.8
)
Net income (loss)
$
80.8

 
$
36.2

 
$
(67.5
)
 
$
81.5

Earnings (loss) per share(1):
 
 
 
 
 
 
 
Basic
$
0.57

 
$
0.26

 
$
(0.49
)
 
$
0.60

Diluted
$
0.57

 
$
0.26

 
$
(0.49
)
 
$
0.60

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
140.8

 
138.1

 
137.4

 
135.9

Diluted
141.4

 
138.7

 
137.4

 
136.3


[2] ludes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.(4) Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.
[3]
Includes change in financial assets of $10.4 million.
[4]
Includes impairment charges of $221.8 million and restructuring charges and other termination benefits of $18.0 million.
[5]
Includes acquisition-related charges and contingent consideration adjustments of $53.2 million.
[6] The sum of individual per share amounts may not equal due to rounding.
[7] The net sales by geography is derived from the location of the entity that sells to a third party.
[8] Includes net sales from our OTC contract manufacturing business.
[9]
Includes Ireland net sales of $23.4 million, $25.7 million, and $30.4 million for the years ended December 31, 2019, December 31, 2018, and December 31, 2017, respectively.